Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.51 |
| ▸ | OPRD1 | P41143 | 8/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 8/20 | 0.51 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.50 |
| ▸ | SLC2A4 | P14672 | 1/20 | 0.48 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023197 | 0.85 | CXCR4 (0.54) | SIGMAR1CXCR4 | |
| SCHEMBL23022836 | 0.85 | CXCR4 (0.54) | SIGMAR1CXCR4 | |
| SCHEMBL23004820 | 0.82 | CXCR4 (0.54) | SIGMAR1CXCR4 | |
| SCHEMBL23023005 | 0.82 | SIGMAR1 (0.54) | SIGMAR1CXCR4 | |
| SCHEMBL23023007 | 0.82 | CXCR4 (0.54) | SIGMAR1CXCR4 | |
| SCHEMBL23023006 | 0.82 | SIGMAR1 (0.54) | SIGMAR1CXCR4 | |
| SCHEMBL23022989 | 0.82 | SIGMAR1 (0.54) | SIGMAR1CXCR4 | |
| SCHEMBL23023184 | 0.82 | CHRM2 (0.58) | SIGMAR1CXCR4CYP1A2CYP3A4 | |
| SCHEMBL23023029 | 0.81 | SIGMAR1 (0.77) | SIGMAR1 | |
| SCHEMBL23023177 | 0.81 | SIGMAR1 (0.77) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2021-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210053997-A1 | TRNA SYNTHETASE INHIBITORS | TRMT1, AARS1, GARS1 | SIGMAR1 2321/4885OPRM1 3187/4885OPRD1 3356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.